Accueil   Diary - News   All news LXREPAIR secures €1.1 million from seed funds for the development of its diagnostic kits in radiotherapy and chemotherapy

LXREPAIR secures €1.1 million from seed funds for the development of its diagnostic kits in radiotherapy and chemotherapy

 

Grenoble, Sept 6th 2017 - LXREPAIR, a French company specialized in the development of disruptive technologies for DNA repair characterization, announces it has raised €1.1M from KREAXI, CEAInvestment, XPAND INVESTMENT Ltd of the KIS Group, Grenoble Angels, Savoie Mont-Blanc Angels, Gentiane Participation and individual investors.

 

The funds will be used to complete LXRepair clinical proofs of concepts in oncology, to obtain the CE marking of the kits and for international business development.

 

 

Read the press release

By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Service. More information... Close